Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis b surface antigen recombinant, quantity: 5 microgram - injection, suspension - excipient ingredients: aluminium; water for injections; sodium chloride; borax - for use in the immunisation against infection caused by all known subtypes of hepatitis b virus. indications as at 17 november 2000: h-b-vax ii is indicated for immunisation against infection caused by all known subtypes of hepatitis b virus. adolescent vaccination is not necessary for children who have received a primary course of hepatitis b vaccine. vaccination is recommended in adults who are at substantial risk of hepatitis b virus infection and have demonstrated or judged to be susceptible. vaccination of individuals who have antibodies against hepatitis b virus from a previous infection is not necessary.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 60 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 30 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - etoricoxib, quantity: 120 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; calcium hydrogen phosphate; croscarmellose sodium; magnesium stearate; titanium dioxide; lactose monohydrate; hypromellose; triacetin; iron oxide yellow; indigo carmine aluminium lake - cipla etoricoxib is indicated for: - symptomatic treatment of the signs and symptoms of osteoarthritis (oa). - treatment of acute gouty arthritis. - treatment of acute pain, including that related to primary dysmenorrhea and minor dental procedures. the decision to prescribe a selective cox-2 inhibitor should be based on an assessment of the individual patient's overall risks.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - fluoxetine hydrochloride, quantity: 22.36 mg (equivalent: fluoxetine, qty 20 mg) - tablet, dispersible - excipient ingredients: magnesium stearate; crospovidone; maize starch; saccharin sodium; microcrystalline cellulose; colloidal anhydrous silica; flavour - indications as at 4 september 2002 : indicated for the treatment of major depression. obsessive compulsive disorder (ocd). premenstrual dysphoric disorder (pmdd) as defined by the diagnostic and statistical manual fourth edition (dsm-iv) criteria. the essential features of pmdd, according to the dsm-iv, include markedly depressed mood, anxiety or tension, affective lability and persistent anger or irritability. other features include decreased interest in usual activities, difficulty concentrating, lack of energy, change in appetite or sleep and feeling out of control. physical symptoms associated with pmdd include breast tenderness, headache, joint and muscle pain, bloating and weight gain. these symptoms occur regularly during the luteal phase and remit within a few days following onset of menses; the disturbance markedly interferes with work or school or with usual social activities and relationships with others.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - amoxicillin sodium, quantity: 1060 mg (equivalent: amoxicillin, qty 1000 mg) - injection, powder for - excipient ingredients: - fisamox is indicated in the treatment of infections due to susceptible strains of the organisms listed below. fisamox powder for injection is intended for use where the patients condition precludes the administration of the oral form. therapy should be guided by bacteriological studies, including sensitivity tests, and by clinical response. however in emergency cases where the causative organism has not yet been identified, therapy with amoxycillin may be useful. clinical judgement will decide whether combination with another antibiotic would provide a sufficiently broad spectrum of activity pending sensitivity test results. septicaemia (bacterial) h. influenzae, e. coli (see microbiology), p. mirabilis, streptococci, s. pneumoniae, s. faecalis and salmonella typhi. skin and skin structure streptococci, non-beta-lactamase-producing staphylococci, e. coli (see microbiology). respiratory, acute and chronic h. influenzae, streptococci, s. pneumoniae, non-beta-lactamase-producing staphylococci, e. coli (see microbiology). genito-urinary tract (complicated and uncomplicated), acute and chronic e. coli (see microbiology), p. mirabilis and s. faecalis. gonorrhoea n. gonorrhoeae (non-beta-lactamase-producing) prophylaxis of endocarditis fisamox may be used for the prophylaxis of bacterial endocarditis in individuals at particular risk, such as those with prosthetic heart valves or those who have previously had endocarditis.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 50 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; sodium starch glycollate; colloidal anhydrous silica; purified talc; disodium edetate; magnesium stearate; microcrystalline cellulose; titanium dioxide; lactose monohydrate; hypromellose; indigo carmine; sunset yellow fcf; iron oxide yellow; macrogol 4000; erythrosine - this product accepted for registration as 'currently supplied' at the time of commencement of the act. amended product information (variation to pregnancy statement) was approved as specified in the letter of 13 august 92 from dr bijoy varma. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clozapine, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; colloidal anhydrous silica; maize starch; purified talc; magnesium stearate; povidone - clozaril is indicated in treatment-resistant schizophrenic patients only, i.e. schizophrenic patients who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - clozapine, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; maize starch; colloidal anhydrous silica; povidone; magnesium stearate; purified talc - clozaril is indicated in treatment-resistant schizophrenic patients only, ie. schizophrenic patients who are non-responsive to, or intolerant of other antipsychotic drugs. non-responsiveness is defined as a lack of satisfactory clinical improvement despite the use of adequate doses of at least two classes of marketed antipsychotic drugs prescribed for reasonable durations. intolerance is defined as the impossibility to achieve adequate benefit with other antipsychotic drugs because of severe and untreatable neurological adverse reactions (extrapyramidal side effects or tardive dyskinesia).

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - adrenaline (epinephrine), quantity: 0.5 mg/ml - injection, solution - excipient ingredients: sodium metabisulfite; water for injections; sodium chloride; hydrochloric acid - for the emergency treatment of anaphylactic reactions to insect stings through immediate self administration by individuals with a history of hypersensitivity to insect stings. epipen and epipen jr. are designated as emergency supportive therapy only and are not a replacement or substitute for subsequent medical or hospital care, nor are they intended to supplant insect venom hyposensitization. indications as at 17 june 2003: for the emergency treatment of anaphylaxis (acute severe allergic reactions) due to insect stings, drugs or other allergens.